In a report released today, Gbola Amusa from Chardan Capital maintained a Hold rating on Vascular Biogenics (NASDAQ: VBLT), with a price target of $3. The company’s shares opened today at $1.65, close to its 52-week low of $1.58.
Amusa noted:
“We will not see interim data from the OVAL trial itself until 4Q19, after 60 patients have been treated with 2 months follow-up.”
According to TipRanks.com, Amusa is a 5-star analyst with an average return of 23.7% and a 52.6% success rate. Amusa covers the Healthcare sector, focusing on stocks such as Spring Bank Pharmaceuticals Inc, Nightstar Therapeutics Limited, and Applied Genetic Technologies.
The word on The Street in general, suggests a Hold analyst consensus rating for Vascular Biogenics with a $3 average price target.
See today’s analyst top recommended stocks >>
Based on Vascular Biogenics’ latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $7.18 million. In comparison, last year the company had a GAAP net loss of $4.87 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Vascular Biogenics Ltd. is in the clinical-stage biopharmaceutical company, which engages in the discovery, development and commercialization of first-in-class treatments for cancer. It offers different programs for cancer and inflammatory disease patients such as vascular targeting system and Lecinoxoids.
